@article{JTD5527,
author = {Jae Seung Lee and Joon Beom Seo and Sang Min Lee and Tai Sun Park and Sei Won Lee and Yeon-Mok Oh and Ji-Hyun Lee and Eun-Kyung Kim and Tae-Hyung Kim and Joo Hun Park and Seung Soo Sheen and Seong Yong Lim and Ina Jung and Sang-Do Lee},
title = {Pharmacological treatment response according to the severity of symptoms in patients with chronic obstructive pulmonary disease},
journal = {Journal of Thoracic Disease},
volume = {7},
number = {10},
year = {2015},
keywords = {},
abstract = {Background: Pharmacological management of chronic obstructive pulmonary disease (COPD) is recommended according to the individualized assessment of symptoms and exacerbation risks. The aim of this study was to determine the relationship between the baseline Modified British Medical Research Council (mMRC) dyspnea scale and the COPD Assessment Test (CAT) score and pharmacological treatment response in patients with COPD.
Methods: A total of 102 stable COPD patients who were enrolled in prospective cohort studies were analyzed. Pharmacological treatment responses after a 3-month treatment were assessed by changes on the mMRC dyspnea scale, CAT scores, and spirometric pulmonary functions.
Results: Sixty-two patients with a mMRC dyspnea scale ≤1 were classified as having “less dyspnea” and 40 patients with a mMRC dyspnea scale ≥2 as having “more dyspnea”. After a 3-month treatment, the mean mMRC dyspnea scale in the “more dyspnea” group was significantly decreased versus the “less dyspnea” group; however, there were no significant differences in CAT score changes or spirometric pulmonary function changes between the two groups. Baseline mMRC scales (Spearman’s rho =−0.591, P},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/5527}
}